S100A8 and S100A9 in Cancer
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2023-05 · 1878 (3) · 188891
DOI: 10.1016/j.bbcan.2023.188891 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023-05. Verfasst von Yu Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China; Cancer Rese…. Hauptthemen laut MEDLINE: Calgranulin A, Neoplasms. Die Arbeit wurde bisher 174-mal zitiert (Crossref) und nennt 256 Literaturangaben. Gefördert von: Changsha Science and Technology Bureau, National Natural Science Foundation of China, Science and Technology Program of Hunan Province.
Abstract (Originalsprache)
S100A8 and S100A9 are Ca2+ binding proteins that belong to the S100 family. Primarily expressed in neutrophils and monocytes, S100A8 and S100A9 play critical roles in modulating various inflammatory responses and inflammation-associated diseases. Forming a common heterodimer structure S100A8/A9, S100A8 and S100A9 are widely reported to participate in multiple signaling pathways in tumor cells. Meanwhile, S100A8/A9, S100A8, and S100A9, mainly as promoters, contribute to tumor development, growth and metastasis by interfering with tumor metabolism and the microenvironment. In recent years, the potential of S100A8/A9, S100A9, and S100A8 as tumor diagnostic or prognostic biomarkers has also been demonstrated. In addition, an increasing number of potential therapies targeting S100A8/A9 and related signaling pathways have emerged. In this review, we will first expound on the characteristics of S100A8/A9, S100A9, and S100A8 in-depth, focus on their interactions with tumor cells and microenvironments, and then discuss their clinical applications as biomarkers and therapeutic targets. We also highlight current limitations and look into the future of S100A8/A9 targeted anti-cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China; Cancer Research Institute, School of Basic Medicine Sciences, Xiangya School of M…
- Cancer Research Institute, School of Basic Medicine Sciences, Xiangya School of Medicine, Central South University, Changsha, China.
Förderung
- Changsha Science and Technology Bureau
- National Natural Science Foundation of China
- Science and Technology Program of Hunan Province
- Hunan Provincial Science and Technology Department
- Ministry of Education of the People's Republic of China
Zitieren
APA
Chen, Y., Ouyang, Y., Li, Z., Wang, X., & Ma, J. (2023). S100A8 and S100A9 in Cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1878(3), 188891. https://doi.org/10.1016/j.bbcan.2023.188891
Vancouver
Chen Y, Ouyang Y, Li Z, Wang X, Ma J. S100A8 and S100A9 in Cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2023;1878(3):188891. doi:10.1016/j.bbcan.2023.188891
BibTeX
@article{Chen2023,
author = {Chen, Yu and Ouyang, Yuzhen and Li, Zhixin and Wang, Xiufang and Ma, Jian},
title = {S100A8 and S100A9 in Cancer},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2023},
volume = {1878},
number = {3},
pages = {188891},
doi = {10.1016/j.bbcan.2023.188891}
}
EUVIMED